Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a price target of $26.00. Larry Biegelsen has given his Buy ...

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Bausch + Lomb (BLCO) to $26 from $23 and keeps an Overweight rating ...

Bausch + Lomb scaled up its revenue guidance for the year after swinging to a profit in the latest quarter on the back of sales growth in each of its business segments.

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Cathleen McCabe, MD has joined Bausch + Lomb as strategic medical advisor. Palvella Therapeutics named Matthew E. Korenberg as CFO. Disc Medicine appointed Rahul Kaushik as CTO. Inspire, an online ...

Banks and private credit firms are competing to provide at least $5 billion of debt financing to help fund a potential buyout of Bausch + Lomb, according to people with knowledge of the matter. A ...

Bausch Health turned down recent debt-restructuring proposals from bondholders as it explores a sale of its Bausch + Lomb vision care subsidiary that could bring in billions of dollars to pay ...

According to the report, bondholders sought to restructure the company's debt to avoid filing for bankruptcy, which included an offer to swap some debt for equity in the Bausch + Lomb unit.

The company reports revenues under five segments — Salix, International, Diversified Products, Solta Medical and Bausch + Lomb. Salix revenues totaled $642 million, up 5% year over year.